Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2000

View Archived Issues

Licensing opportunity from NIH: method of refolding recombinant endostatin

Licensing opportunity from NIH: neuropeptide for pain regulation, blood pressure control

Maxim looking to acquire Cytovia

MedImmune and Alkermes to develop inhalable form of MAb targeting RSV

Periodontix and PPL Therapeutics successfully complete feasibility study for transgenic P-113

Phase III results reported for Hemolink in cardiac bypass patients

Dura to launch second Allergan product

Celera Genomics and Geron to collaborate on human pluripotent stem cell genomics

Celgene and Novartis d-methylphenidate license agreement now in effect

Cel-Sci begins another collaboration with the NCI

Millennium and Lilly extend cardiovascular collaboration

Advanced Life Sciences to develop natural melanoma treatment

Lanepitant proves ineffective in reducing osteoarthritis pain

North American Vaccine shareholders approve Baxter acquisition

Oncolytics successfully completes initial toxicology studies of Reolysin

TKT files BLA for Fabry's disease treatment

Synsorb Biotech highlights achievements of two lead products during Q1

Data presented at Sitges workshop support further clinical development of DAPD

DMP-450: phase I/II results suggest promising antiviral efficacy, favorable toxicity profile

Pfizer/Warner-Lambert merger completed

Combinations containing SJ-3366 prove additive to synergistic against HIV isolates

Itavastatin favorably affects lipid profile without influencing glucose metabolism in NIDDM

Calcilytic NPS-2143 demonstrates bone anabolic effects in ovariectomized rats

Water-soluble MMP inhibitors and their use reported by Aventis

Merck and Banyu jointly develop new agents for obesity and its complications

Early development projects at Aventis include new erythromycin antibiotics

Combination therapy for heart failure

Selective alpha1A-adrenoceptor antagonists with an oxazolidinone structure

Inhibitors of intracellular signal transduction discovered by Ariad

New antimicrobial mutilin derivatives and their use described in patent issued to SB

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...